Respiratory Syncytial Virus, Human
"Respiratory Syncytial Virus, Human" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The type species of PNEUMOVIRUS and an important cause of lower respiratory disease in infants and young children. It frequently presents with bronchitis and bronchopneumonia and is further characterized by fever, cough, dyspnea, wheezing, and pallor.
| Descriptor ID |
D018113
|
| MeSH Number(s) |
B04.820.455.600.670.600.750.730
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Respiratory Syncytial Virus, Human".
Below are MeSH descriptors whose meaning is more specific than "Respiratory Syncytial Virus, Human".
This graph shows the total number of publications written about "Respiratory Syncytial Virus, Human" by people in this website by year, and whether "Respiratory Syncytial Virus, Human" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 0 | 3 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 2 | 3 |
| 1999 | 4 | 2 | 6 |
| 2000 | 2 | 0 | 2 |
| 2001 | 1 | 0 | 1 |
| 2003 | 4 | 0 | 4 |
| 2004 | 2 | 1 | 3 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 3 | 0 | 3 |
| 2008 | 2 | 0 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 2 | 0 | 2 |
| 2012 | 5 | 0 | 5 |
| 2013 | 6 | 0 | 6 |
| 2014 | 6 | 1 | 7 |
| 2015 | 4 | 0 | 4 |
| 2016 | 5 | 3 | 8 |
| 2017 | 6 | 0 | 6 |
| 2018 | 5 | 1 | 6 |
| 2019 | 4 | 0 | 4 |
| 2020 | 5 | 0 | 5 |
| 2021 | 9 | 3 | 12 |
| 2022 | 6 | 0 | 6 |
| 2023 | 9 | 0 | 9 |
| 2024 | 4 | 1 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Respiratory Syncytial Virus, Human" by people in Profiles.
-
Infant-derived human nasal organoids exhibit relatively increased susceptibility, epithelial responses, and cytotoxicity during RSV infection. J Infect. 2024 Dec; 89(6):106305.
-
Respiratory Syncytial Virus Vaccination in the Adult Pulmonary Patient. Chest. 2024 Nov; 166(5):963-974.
-
Seasonality, Clinical Characteristics, and Outcomes of Respiratory Syncytial Virus Disease by Subtype Among Children Aged <5 Years: New Vaccine Surveillance Network, United States, 2016-2020. Clin Infect Dis. 2024 May 15; 78(5):1352-1359.
-
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 07; 73(9):209-214.
-
Respiratory viral detection in the plasma and cerebrospinal fluid (CSF) of young febrile infants. Influenza Other Respir Viruses. 2024 Feb; 18(2):e13250.
-
Disease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged =60 Years - IVY Network, 20 U.S. States, February 2022-May 2023. MMWR Morb Mortal Wkly Rep. 2023 Oct 06; 72(40):1083-1088.
-
American Society of Transplantation and Cellular Therapy Series: #7 - Management of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients. Transplant Cell Ther. 2023 Dec; 29(12):730-738.
-
Potent cross-neutralization of respiratory syncytial virus and human metapneumovirus through a structurally conserved antibody recognition mode. Cell Host Microbe. 2023 08 09; 31(8):1288-1300.e6.
-
In-vivo and human evidence for potential efficacy of therapeutic polyclonal RSV neutralizing antibodies for palivizumab-resistant RSV infections. Virology. 2023 09; 586:115-121.
-
T cell immune profiling of respiratory syncytial virus for the development of a targeted immunotherapy. Br J Haematol. 2023 08; 202(4):874-878.